Feasibility of Docetaxel-cisplatin as 3rd or 4th line treatment for recurrent or unresectable biliary tract cacner.

Feasibility of Docetaxel-cisplatin as 3rd or 4th line treatment for recurrent or unresectable biliary tract cacner. - Feasibility of Docetaxel-cisplatin as 3rd or 4th line treatment for recurrent or unresectable biliary tract cacner.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009212

Enrollment

Registered

2012-11-01

Start date

2012-10-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer

Interventions

Biliary tract cacner patients who has already administered gemcitabine,S-1,and cisplatine or patients who couldn&#39

t adminster such drugs for side effects. Biliary tract cancer patients who has already administered gemcitabine,S-1,and cisplatine or patients who couldn&#39

t adminster such drugs for side effects and reject the option of Docetaxel-cisplatin treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Biliary tract cacner patients who has already administered gemcitabine,S-1,and cisplatine or patients who couldn't adminster such drugs for side effects.

Exclusion criteria

Exclusion criteria: If patients reject.

Design outcomes

Primary

Measure	Time frame
Time to progression	—

Countries

Japan

Contacts

Public ContactRyutaro Mori

Yokohama city university graduated school of medicine Department of Gastroenterological Surgery

045-787-2650

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026